Windtree Announces Positive Topline Results from Its Phase 2 SEISMiC Study of Istaroxime in Early Cardiogenic Shock
April 20, 2022 07:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., April 20, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Participate in the Lytham Partners Spring 2022 Investor Conference
March 31, 2022 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology focused on advancing multiple late-stage interventions for acute cardiovascular and...
Windtree Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Key Business Updates
March 31, 2022 07:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 31, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces Results from Its Phase 2 Study of Lucinactant for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS) and Lung Injury
March 22, 2022 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 22, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Completes Enrollment of Phase 2 Study of Istaroxime in Early Cardiogenic Shock
March 15, 2022 07:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 15, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree to Present at Oppenheimer’s 32nd Annual Healthcare Conference
March 10, 2022 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., March 10, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions...
Windtree Completes Enrollment in Its Phase 2 Study of Lucinactant (KL4 Surfactant) for COVID-19 Associated Lung Injury and Acute Respiratory Distress Syndrome
February 01, 2022 07:30 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Announces U.S. Patent and Trademark Office Issuance of New U.S. Istaroxime Patent
December 15, 2021 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Research Finds U.S. Cardiogenic Shock Patients Have High Hospital Inpatient Mortality and Long Length of Stay – Adding to Previously Reported Need for New Pharmacologic Innovation
November 22, 2021 08:00 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...
Windtree Therapeutics Reports Third Quarter 2021 Financial Results and Provides Key Business Updates
November 10, 2021 16:05 ET
|
Windtree Therapeutics
WARRINGTON, Pa., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology company focused on advancing multiple late-stage interventions for acute...